ECSP23036608A - Compuestos aromáticos que contienen boro y análogos de insulina - Google Patents

Compuestos aromáticos que contienen boro y análogos de insulina

Info

Publication number
ECSP23036608A
ECSP23036608A ECSENADI202336608A ECDI202336608A ECSP23036608A EC SP23036608 A ECSP23036608 A EC SP23036608A EC SENADI202336608 A ECSENADI202336608 A EC SENADI202336608A EC DI202336608 A ECDI202336608 A EC DI202336608A EC SP23036608 A ECSP23036608 A EC SP23036608A
Authority
EC
Ecuador
Prior art keywords
diabetes
mody
compounds containing
aromatic compounds
containing boron
Prior art date
Application number
ECSENADI202336608A
Other languages
English (en)
Inventor
Sachitanand Mali
Jack Steele
Jingxin Liang
Mirna Shaker
Ryan Spencer
Diao Chen
Alborz Mahdavi
Original Assignee
Protomer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protomer Tech Inc filed Critical Protomer Tech Inc
Publication of ECSP23036608A publication Critical patent/ECSP23036608A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación se refiere a nuevos compuestos que incluyen uno o más grupos aromáticos que contienen boro. La presente divulgación se refiere además a composiciones farmacéuticas que contienen tales compuestos, y su uso en la prevención y el tratamiento de trastornos, tales como hiperglucemia, diabetes tipo 2, intolerancia a la glucosa, diabetes tipo 1, obesidad, síndrome metabólico X o dislipidemia, diabetes durante el embarazo, prediabetes, enfermedad de Alzheimer, diabetes MODY 1, MODY 2 o MODY 3, trastornos del estado de ánimo y trastornos psiquiátricos.
ECSENADI202336608A 2020-11-19 2023-05-18 Compuestos aromáticos que contienen boro y análogos de insulina ECSP23036608A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063116050P 2020-11-19 2020-11-19
US202063122338P 2020-12-07 2020-12-07
US202163210968P 2021-06-15 2021-06-15
US202163249868P 2021-09-29 2021-09-29

Publications (1)

Publication Number Publication Date
ECSP23036608A true ECSP23036608A (es) 2023-06-30

Family

ID=79024395

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202336608A ECSP23036608A (es) 2020-11-19 2023-05-18 Compuestos aromáticos que contienen boro y análogos de insulina

Country Status (16)

Country Link
US (1) US20240374735A1 (es)
EP (1) EP4247429A1 (es)
JP (1) JP2024500284A (es)
KR (1) KR20230110505A (es)
AU (1) AU2021382599A1 (es)
CA (1) CA3198757A1 (es)
CO (1) CO2023006369A2 (es)
DO (1) DOP2023000097A (es)
EC (1) ECSP23036608A (es)
IL (1) IL302775A (es)
JO (1) JOP20230110A1 (es)
MX (1) MX2023005935A (es)
PE (1) PE20231948A1 (es)
PH (1) PH12023500012A1 (es)
TW (1) TW202237188A (es)
WO (1) WO2022109078A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317049A (en) * 2022-05-18 2025-01-01 Protomer Tech Inc Aromatic boron-containing compounds and related insulin analogs
WO2024215876A2 (en) * 2023-04-11 2024-10-17 Protomer Technologies, Inc. Compounds containing one or more diboronates and related insulin analogs
JP7634756B2 (ja) * 2023-04-24 2025-02-21 ノヴォ ノルディスク アー／エス グルコース感受性インスリン誘導体
WO2025016992A1 (en) 2023-07-18 2025-01-23 Novo Nordisk A/S Pharmaceutical compositions of insulin derivatives
WO2025128687A1 (en) * 2023-12-11 2025-06-19 University Of Notre Dame Du Lac Glucose-dependent droplets and supramolecular peptide depots for glucose-responsive glucagon delivery

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US906028A (en) 1908-03-27 1908-12-08 Herbert E Jennison Adjustable foot-block for radiators.
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
WO1999034821A1 (en) 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
EP1453860A2 (en) * 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
JP5599543B2 (ja) 2002-05-07 2014-10-01 ノヴォ ノルディスク アー／エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
AU2005208748A1 (en) 2004-01-23 2005-08-11 California Institute Of Technology Engineered proteins, and methods of making and using
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
CN103520735B (zh) 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
EP1836298B1 (en) 2004-12-22 2012-01-18 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
WO2007047668A2 (en) 2005-10-14 2007-04-26 California Institute Of Technology Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells
AU2007224019A1 (en) 2006-03-03 2007-09-13 California Institute Of Technology Site-specific incorporation of amino acids into molecules
JP5313129B2 (ja) 2006-05-02 2013-10-09 アロザイン， インコーポレイテッド 非天然アミノ酸置換ポリペプチド
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
US9996862B2 (en) 2012-07-23 2018-06-12 @Pay Ip Holdings Llc Point of sale email-based e-commerce
WO2014093696A2 (en) * 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
US10640546B2 (en) 2014-06-10 2020-05-05 California Institute Of Technology Non-canonical insulins and their uses
WO2017070617A1 (en) * 2015-10-21 2017-04-27 Case Western Reserve University Diol-modified insulin analogues containing a glucose-regulated conformational switch
CN117624207A (zh) * 2017-11-09 2024-03-01 诺和诺德股份有限公司 葡萄糖敏感性白蛋白结合衍生物
EP3781147A4 (en) * 2018-04-16 2022-04-20 University of Utah Research Foundation Glucose-responsive insulin
JP7640462B2 (ja) * 2019-03-29 2025-03-05 ノヴォ ノルディスク アー／エス グルコース感受性インスリン誘導体
EP4003426A4 (en) * 2019-07-31 2023-07-05 Thermalin Inc. GLUCOSE-REGULATED CONFORMATION SWITCH INSULIN ANALOGS
GB2610490A (en) * 2020-03-31 2023-03-08 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols

Also Published As

Publication number Publication date
US20240374735A1 (en) 2024-11-14
KR20230110505A (ko) 2023-07-24
WO2022109078A1 (en) 2022-05-27
TW202237188A (zh) 2022-10-01
JP2024500284A (ja) 2024-01-09
CO2023006369A2 (es) 2023-05-19
AU2021382599A1 (en) 2023-06-22
EP4247429A1 (en) 2023-09-27
PE20231948A1 (es) 2023-12-05
CA3198757A1 (en) 2022-05-27
PH12023500012A1 (en) 2024-03-11
JOP20230110A1 (ar) 2023-05-18
AU2021382599A9 (en) 2024-08-08
MX2023005935A (es) 2023-05-29
DOP2023000097A (es) 2023-09-29
IL302775A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
ECSP23036608A (es) Compuestos aromáticos que contienen boro y análogos de insulina
DOP2022000110A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
UY39969A (es) Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1
AR039063A1 (es) Derivados de diarilcicloalquilo, procedimiento para su preparacion, medicamento, un proceso para su preparacion, utilizacion de dichos derivados para la preparacion de un medicamento
CL2008002787A1 (es) Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil.
NI201100117A (es) Antagonistas de 4 -- azetidinil - 1 - heteroaril - ciclohexanol del ccr2.
PE20050249A1 (es) Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
BRPI0908406B8 (pt) Derivados de quinoxalinona, processo para a preparação dos mesmos, seu uso e composição farmacêutica
CL2010001159A1 (es) Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros.
UY39968A (es) Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1
AR072072A1 (es) Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
CL2008002356A1 (es) Sulfoxidos de piperazina-amida; sus procesos de preparacion; las composiciones farmaceuticas que los contienen; y su uso en el tratamiento de enfermedades que se modulan con agonistas lxr alfa y/o beta.
CL2024003507A1 (es) Compuestos aromáticos que contienen boro y análogos de insulina relacionados
BRPI1007350B8 (pt) compostos espiro heterocíclicos bicíclicos
CL2023001390A1 (es) Compuestos aromáticos que contienen boro y análogos de insulina
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
AR124101A1 (es) Compuestos aromáticos que contienen boro y análogos de insulina
DOP2025000258A (es) Compuestos que contienen uno o más diboronatos y análogos de insulina relacionados
CO2025013565A2 (es) Compuestos que contienen uno o más diboronatos y análogos de insulina relacionados
AR132407A1 (es) Compuestos que contienen uno o más diboronatos y análogos de insulina relacionados
CL2004001929A1 (es) Compuestos derivados de 1-sulfonil-piperidin-4-il)-1,4-dihidro-benzo[1,3]oxazin-2-ona; proceso de preparacion; composicion farmaceutica; y su uso como reguladores del receptor 5-ht6 en el tratamiento de trastornos alimentarios como obesidad, bulimia,
BR112022008265A2 (pt) Composições farmacêuticas contendo diácido de oligossacarídeo de alginato